Appendix 4D & Half-Year Financial Report
Filed with ASX · · 30 pages · English
● Record 1H FY26 revenue of $6.2 million1, up 48% on the prior corresponding period (1H FY25: $4.2 million), delivering two consecutive record quarters (1Q FY26: $3.0m; 2Q FY26: $3.2m) and a Compound Half-Year Growth Rate (CHGR) of 21% since 2H FY24. ● Gross profit of $3.0 million in 1H FY26, up 63% on the prior corresponding period (1H FY25: $1.8 million), with gross margin increasing to 55% (1H
Story so far
Earlier from Orthocell
- Orthocell Receives $3.0m R&D Tax Refund
- US Market and Operational Update
- Quarterly Activity Report & Appendix 4C
- Orthocell Posts Seventh Straight Record Revenue Quarter
- Orthocell Hits US Milestone - 100 Remplir Units Sold.
Later from Orthocell
- Orthocell Appoints UK Distributor for Remplir
- Remplir Used in 23 Surgeries in Ukrainian soldiers
- OCC Secures Access to 221 U.S. Military Medical Centres
- Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
- First Surgical Use of Remplir in US Department of Defense
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell